# Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

> **NCT05494580** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 29 (actual)

## Conditions studied

- Ovarian Cancer
- Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- Fallopian Tube Carcinosarcoma
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Pamiparib
- **DRUG:** Surufatinib

## Key facts

- **NCT ID:** NCT05494580
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-22
- **Primary completion:** 2024-06-20
- **Final completion:** 2026-01-31
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05494580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05494580, "Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05494580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*